CD274 and neoplasm: While patients with high tumor mutational burden (TMB‐H), including those with MSI‐H (6.2%) and representing 12.2% of the cohort, can benefit from PD‐1/PD‐L1 checkpoint inhibitors such as nivolumab and pembrolizumab [81, 82, 85], the high PD‐L1 positivity observed in non‐hypermutated, MMR‐proficient tumors suggests that additional PRH patients beyond those with high TMB or MSI‐H may also respond favorably to these immunotherapies [86].